1. Introduction
===============

Hepatic steatosis (HS) is a common abnormality occurring in approximately 30% of the general population in the United States,^\[[@R1]\]^ and its clinical importance is being increasingly recognized. The HS is a component of nonalcoholic fatty liver disease, which may progress to steatohepatitis, fibrosis, and even cirrhosis in some patients.^\[[@R2],[@R3]\]^ The HS is associated with insulin resistance and is regarded as a hepatic manifestation of metabolic syndrome^\[[@R4]\]^ also it is a critical in liver transplantation. Donor livers with HS are known to adversely affect the prognosis of liver transplantation recipients.^\[[@R5]\]^

Liver biopsy has been regarded as the standard method for HS assessment. However, this technique is invasive and, thus, is not suitable for screening a large number of subjects at risk and during follow-up examination of patients with HS. Therefore, noninvasive imaging techniques have been used to assess HS in clinical practice and research, and in particular, magnetic resonance (MR) spectroscopy and chemical-shift MR imaging are currently considered the most accurate imaging techniques.^\[[@R6],[@R7]\]^

Computed tomography (CT) facilitates HS assessment in a quantitative manner using CT indices based on the measurement of liver attenuation. Although CT is not accurate in diagnosing mild HS,^\[[@R7]\]^ it enables the diagnosis of moderate to severe HS with a high specificity.^\[[@R6],[@R8],[@R9]\]^ Compared with MR spectroscopy and MR imaging, CT is more widely available and easier to perform. Thus, CT has been used to identify subjects with clinically significant HS for living liver donor evaluation^\[[@R8],[@R10]--[@R12]\]^ as well as in researches involving large-scale cohorts.^\[[@R13]--[@R16]\]^ Furthermore, CT has also been utilized to assess the change in HS in longitudinal cohort studies^\[[@R17]\]^ and therapeutic clinical trials.^\[[@R18],[@R19]\]^ Although the performance of CT in diagnosing HS has been evaluated in a few studies,^\[[@R7]--[@R11],[@R20]\]^ no prior evaluation has been conducted on CT being a reliable technique for monitoring longitudinal change in HS.

Therefore, this study aimed to evaluate the feasibility of CT for assessing the change in HS during longitudinal follow-up by employing pathological HS as the reference standard.

2. Materials and methods
========================

This study was approved by the institutional review board of Asan Medical Center. The requirement for informed consent was waived for this retrospective review.

2.1. Study population
---------------------

From April 2001 to October 2016, a total of 6366 subjects underwent living liver donor work-up at our institution. The inclusion criteria for hepatic donor evaluation were the absence of any documented liver disease, negative serologic findings for hepatitis B or C, and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels below 3 times of the upper normal limit. Routine living liver donor evaluation included laboratory blood tests, abdominal ultrasonography (US), abdominal CT, and US-guided percutaneous liver biopsy. For the actual liver donors, intraoperative liver biopsy was routinely performed before donor liver resection for the final confirmation of the suitability of donors' liver for liver transplantation. Among the donor candidates, we retrospectively searched for the subjects who fulfill the inclusion and exclusion criteria of this study. The inclusion criteria were subjects who underwent liver biopsy twice or more times, and those who underwent liver CT within 1 week of each liver biopsy. The exclusion criteria were excess alcohol consumption, liver disease other than HS, and unavailable non-enhanced CT images. Thirty-eight living liver donor candidates (27 men and 11 women; mean age, 29.5 years; age range, 18--52 years) who met these criteria were included in this study. All subjects underwent liver biopsy twice within a mean time interval of 580.9 ± 926.7 days (range, 16--3963 days). The mean time interval between liver biopsy and CT was 0.9 ± 1.8 days (range, 0--7 days); 48 (63.2%) of 76 CT scans were performed on the same day of liver biopsy. The initial liver biopsy was performed by ultrasound-guided liver biopsy in all 38 subjects. The 2nd liver biopsy was performed either by US-guided liver biopsy (n = 21) or by intraoperative wedge resection biopsy (n = 17) which was routinely performed during donor hepatectomy in our institution. For 21 donors who underwent US-guided liver biopsy twice, liver biopsy was repeated for the follow-up examination of significant hepatic steatosis detected at the initial biopsy, which precludes liver donation in 18 subjects. The remaining 3 subjects did not donate liver at the time of initial biopsy because of the recipients' refusal to surgery, and then, 2048--3963 days after the initial donor work-up, the subjects were re-enrolled for donor evaluation.

2.2. CT examinations
--------------------

Because of a long study period, various scanners and scan techniques were employed for CT examinations. The CT scans were performed using 16- (Sensation 16 \[n = 37\], Siemens, Erlangen, Germany; and Lightspeed 16 \[n = 17\], GE Medical System, Milwaukee, Wis) or 64- (Definition \[n = 22\], Siemens) multidetector row CT scanners. Non-enhanced images were obtained by employing a beam collimation of 16 × 1.5 mm (Sensation 16), 8 × 2.5 mm (Lightspeed 16), or 24 × 1.2 mm (Definition); a spiral pitch of 1 (Sensation 16 and Definition) or 1.35 (Lightspeed 16); a tube voltage of 100 (n = 13) or 120 (n = 63) kVp; and a tube current of 150 mAs (Lightspeed 16) or of a variable mA (Sensation 16 and Definition) with an automatic exposure control (Care Dose 4D; Siemens; a maximum effective dose of 200 mA). Images were reconstructed at a section thickness of 5 mm and at an interval of 5 mm.

Four readers, including one of the abdominal radiology faculty members (Reader-1, with 12 years of experience in abdominal radiology), 1 abdominal imaging fellow (Reader-2), and 2 medical school students (Reader-3 and -4, in the 2nd and 3rd year of medical college, respectively) independently performed quantitative analysis of non-enhanced CT images. The CT images were anonymized and randomized for review. All readers were blinded to the results of liver biopsy and those of the CT analysis conducted by other readers. Hepatic attenuation was measured by averaging Hounsfield unit (HU) values of 8 1.5-cm^2^ circular regions-of-interest (ROIs): 2 ROIs were placed at 2 different sites in each segment of the right hepatic lobe (hepatic segments V, VI, VII, and VIII according to the Couinaud system). Splenic attenuation was obtained by averaging HU values of 3 1.5-cm^2^ circular ROIs placed in the upper, middle, and lower thirds of the spleen (Fig. [1](#F1){ref-type="fig"}). For both hepatic and splenic attenuation measurements, ROIs were placed under special care so as to exclude macroscopic vessels. Before performing image review, the 2 medical school students studied the cross-sectional anatomy of the liver using web contents (<https://www.imaios.com/en/e-Anatomy>) and were trained under the supervision of a senior radiologist (S.S.L.) for the placement of ROIs in the liver and the spleen in 5 example cases which are not included in this study. CT~L-S~ was used as the CT index for assessing HS in this study and was calculated by subtracting the mean HU value of the spleen from that of the liver.^\[[@R20]\]^ The change in CT~L-S~ between the 1st and the 2nd CT scan (ΔCT~L-S~) was calculated as CT~L-S~ on the 2nd CT minus CT~L-S~ on the 1st CT.

![Non-enhanced axial CT images of a 30-year old male living liver donor candidate. **A** and **B**, 4 1.5-cm circular ROIs (white circles) were placed in the hepatic segments VIII and VII that is devoid of macroscopic vessels. A 1.5-cm circular ROI was positioned in the spleen (black circle). The values obtained by the readers 1, 2, 3, and 4 after subtracting spleen attenuation from liver attenuation (CT~L-S~) measurements were −21.5, −23.8, −22.7, and −21.9 at the 1st CT scan (**A**) and 4.4, 2.1, 2.9, and 3.4, respectively, at the 2nd CT scan (**B**). Liver biopsy revealed moderate hepatic steatosis (60%) at the time of the 1st CT scan (**A**) and mild hepatic steatosis (25%) at the time of the 2nd CT scan (**B**).](medi-98-e15606-g001){#F1}

2.3. Liver biopsy
-----------------

All liver biopsies were performed as a part of routine living liver donor evaluation at our institution. The US-guided percutaneous liver biopsy was performed using an 18-gauge needle (Stericut 18G coaxial; TSK Laboratory, Tochigi, Japan). Two or more biopsy specimens, with each section measuring approximately 1.5 cm in length, were obtained at 2 different sites from the right hepatic lobe. Intraoperative liver biopsy was performed by wedge resection at the time of donor liver resection. Approximately 1 × 1 × 1 cm samples of liver tissues were obtained from sites deeper than 1 cm from the liver surface at both right and left hepatic lobes. Hematoxylin--eosin and Masson trichrome stains were used to stain biopsy specimens. The degree of HS was visually assessed using a percentage scale, i.e., the amount of liver parenchyma replaced by steatotic droplets. The HS was graded as none (\<5%), mild (5%--29%), moderate (30%--59%), or severe (≥60%). The change in HS between the 1st and 2nd biopsies (ΔHS) was calculated by subtracting HS (%) estimated during the 1st biopsy from the HS (%) estimated during the 2nd biopsy. For the analysis of the diagnostic performance of ΔCT~L-S~ in detecting ≥5% ΔHS and ≥10% ΔHS, the study population was divided into 2 sets of subgroups, i.e. those with significant change in HS and those without significant change in HS, using the threshold ΔHS values of 5 and 10%.

2.4. Clinical information
-------------------------

The body weight, height, and laboratory data, such as the levels of serum AST, ALT, and total bilirubin, obtained within 1 week prior to each biopsy were recorded. The mean time interval between liver biopsy and laboratory tests was 1.3 ± 1.9 days (range, 0--7 days) with 56.6% (43/76) of laboratory data obtained on the same day of liver biopsy. Body mass index (BMI) was calculated as weight (kg) divided by the squared value of height (m^2^). As the clinical indices for predicting hepatic steatosis, AST--ALT ratio was calculated by dividing serum AST (IU/L) with ALT (IU/L) value, and hepatic steatosis index (HSI) was calculated as reported previously^\[[@R21]\]^; HSI = 8·AST--ALT ratio + BMI (+2 if DM; 2+ if female). The changes in BMI (ΔBMI), AST--ALT ratio (ΔAST--ALT ratio), and HSI (ΔHSI) were assessed as the difference value calculated by subtracting the values at the time of the 1st liver biopsy from those at the time of the 2nd liver biopsy.

2.5. Statistical analysis
-------------------------

The clinical and histologic features at the initial and the 2nd liver biopsy were compared using the paired *t* test or Fisher\'s exact test. The correlation of ΔHS with ΔCT~L-S~ and clinical indices (ΔBMI, ΔAST-ALT ratio, ΔHSI) were evaluated using the linear regression analysis. The correlation coefficients for ΔCT~L-S~ were compared with those for the clinical indices using the z-test. Interobserver agreement among the readers with regard to the measurement of ΔCT~L-S~ values and CT~L-S~ values on the 1st CT scan was evaluated using the intraclass correlation coefficient (ICC). The ICCs of ΔCT~L-S~ were compared with those of CT~L-S,~ and the ICC of ΔCT~L-S~ measured by the 2 radiologists was compared with the ICC of ΔCT~L-S~ measured by the 2 medical students using the z-test. Interobserver measurement error ranges among the 4 readers in the measurement of ΔCT~L-S~ and CT~L-S~ values were evaluated using repeatability coefficient.^\[[@R22]\]^ The interobserver measurement error range was used as the threshold for ΔCT~L-S~ while calculating the sensitivity, specificity, and accuracy of ΔCT~L-S~ in detecting ≥5% ΔHS and ≥10% ΔHS. Statistical analysis was performed using SPSS statistics v.22 software (IBM, New York, NY) and MedCalc software (MedCalc Software, Mariakierke, Belgium). A *P* value of \< .05 was considered to indicate a statistically significant difference.

3. Results
==========

3.1. Characteristics of study population
----------------------------------------

The clinical and histological characteristics of the study population are summarized in Table [1](#T1){ref-type="table"}. At the time of the 1st liver biopsy, the mean degree of HS was 22.6 ± 22.7%, and 18 subjects (47.3%) had moderate to severe HS. The degree of HS significantly decreased at the 2nd liver biopsy (7.4 ± 8.3%, *P* \< .001), with moderate hepatic steatosis being present only in 1 (2.6%) subject. There was also a significant decrease in BMI (*P* = .011), AST (*P* = .02), ALT (*P* = .003), total bilirubin (*P* = .018), HSI (*P* = .001), and CT~L-S~ (*P* \< .001) at the time of 2nd liver biopsy compared with the values at the 1st biopsy.

###### 

Characteristics of study population.

![](medi-98-e15606-g002)

3.2. Changes in hepatic steatosis, CT index, and clinical indices
-----------------------------------------------------------------

Between the 1st and the 2nd liver biopsy, the change in HS ranged from −65 to 30%. Seven subjects had no HS at both 1st and 2nd biopsy (ΔHS = 0%); the 2nd biopsy in these subjects were performed by means of an intraoperative wedge resection biopsy during a donor hepatectomy. Twenty-four subjects had a decreased HS at the 2nd biopsy compared with the 1st biopsy, with ΔHS ranging from −1 to −65%, while nine subjects showed an increased HS with ΔHS of 1 to 30%. The ΔHS had a significant inverse correlation with ΔCT~L-S~ for all 4 readers (*r* = 0.65, 0.57, 0.63, and 0.62 for readers 1, 2, 3, and 4, respectively; *P* \< .001), with the regression coefficients of −1.64, −1.47, −1.61, and −1.51, respectively, for readers 1, 2, 3, and 4 (Fig. [2](#F2){ref-type="fig"}), which indicates that the ΔHS decreases by 1.47 to 1.64% for each unit value increase in ΔCT~L-S~. The Δ HS also showed significant correlations with ΔBMI (*r* = 0.46, *P* = .004), ΔAST-ALT ratio (*r* = 0.41, *P* = .01), and ΔHSI (*r* = 0.59, *P* \< .001). The correlation coefficients for ΔCT~L-S~ were slightly higher than those for ΔBMI (*P* = .242--.522), ΔAST-ALT ratio (*P* = .155--.372), and ΔHSI (*P* = .660--.930) without any statistically significant difference.

![Scatter plots for the change in hepatic steatosis (ΔHS) according to the change in CT~L-S~ value (ΔCT~L-S~) measured by 4 readers. **A** and **B**, the circles indicate data points measured by the 4 readers. The same scatter plot was presented with the regression lines for the values measured by the 4 readers (**A**) or with reference lines (**B**). **A**, the oblique dotted lines were the regression lines. **B**, the vertical red dotted lines indicate the interobserver measurement error range of ΔCT~L-S~ (−8.9--8.9). The horizontal grey dotted line indicates no change in hepatic steatosis between the 1st and the 2nd biopsies (ΔHS = 0%). The grey-colored right upper and left lower quadrants of the scatter plot indicate a change in hepatic steatosis, which is inconsistent with the change in ΔCT~L-S~. Note that most data points in the horizontal grey dotted line and grey-colored quadrants are within the interobserver measurement error range of ΔCT~L-S~.](medi-98-e15606-g003){#F2}

3.3. Interobserver agreement of CT index measurements
-----------------------------------------------------

The ICC for the ΔCT~L-S~ measurements taken by the 4 readers was 0.89 (95% confidence interval \[CI\], 0.82--0.93), which was significantly lower than the ICC (0.96; 95% CI, 0.92--0.98\]) for CT~L-S~ measurements taken on the 1st CT scans (*P* = .023). The ICC for ΔCT~L-S~ measured by 2 radiologists (0.95; 95% CI, 0.91--0.97) did not significantly differ from the ICC for ΔCT~L-S~ measured by 2 medical students (0.91; 95% CI, 0.83--0.95; *P* = .0215). The interobserver measurement error range among the 4 readers, represented by the repeatability coefficients, was 8.9 (95% CI, 7.9--10.2) for ΔCT~L-S~ and 6.7 (95% CI, 5.9--7.7) for CT~L-S~ on the 1st CT scans.

3.4. Detection of change in CT~L-S~ using CT index
--------------------------------------------------

In 7 subjects with no absolute change in HS between 2 biopsies (ΔHS = 0%), ΔCT~L-S~ for 4 readers ranged from −9.2 to 11.6. As shown in Fig. [2](#F2){ref-type="fig"} and Table [2](#T2){ref-type="table"}, the ΔCT~L-S~ beyond the interobserver measurement error range (i.e., ΔCT~L-S~ \> 8.9 or \<−8.9) was more frequently associated with a change in HS that is consistent with the change in CT~L-S~ (i.e., a decrease in HS in cases of positive ΔCT~L-S~ or vice versa) than the ΔCT~L-S~ within the interobserver measurement error range, with statistically significant differences noted for the values measured by the readers 1 (*P* = .012) and 4 (*P* \< .001). Moreover, changes in HS consistent with the changes in CT~L-S~ were noted in 83.3% (13/15) to 100% (15/15) for the ΔCT~L-S~ beyond the interobserver measurement error range (Fig. [1](#F1){ref-type="fig"}) but were observed only in 43.5% (8/19) to 61.5% (16/26) for the ΔCT~L-S~ within the interobserver measurement error range.

###### 

The change in hepatic steatosis according to the magnitude of change in CT index.
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When the interobserver measurement error range was used as the threshold value to indicate a meaningful change in HS (i.e., ΔCT~L-S~ \> 8.9 or \<−8.9), the sensitivity and specificity for detecting an absolute change of ≥5% in HS were in the range of 40.7 to 66.7% and 77.8 to 100%, respectively, and the sensitivity and specificity for detecting an absolute change ≥10% in HS ranged from 47.8 to 79.9% and from 86.7 to 100%, respectively (Table [3](#T3){ref-type="table"}).

###### 

The performance of ΔCT~L-S~ beyond measurement error range in the detection of the change in hepatic steatosis.
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4. Discussion
=============

Our study evaluated the feasibility of CT for assessing the change in HS by using the pathologic degree of HS as the reference standard. As the quantitative CT index, we used CT~L-S~ in this study because this index is best validated for its accuracy^\[[@R7],[@R8],[@R11],[@R20]\]^ and normal reference range^\[[@R20]\]^ among CT indices.

Our study demonstrated a statistically significant correlation between ΔCT~L-S~ and ΔHS, indicating that it is feasible to use the change in CT~L-S~ value for assessing the change in HS during longitudinal follow-up. However, our results also indicated that the actual clinical utility of ΔCT~L-S~ in the follow-up of patients with HS may be limited because of the following reasons. First, the correlation between ΔCT~L-S~ and ΔHS in our study was not very strong, with correlation coefficients ranging from 0.571 to 0.65 among the 4 readers. The change in clinical indices also showed a significant correlation with ΔHS, although their correlation coefficients were slightly lower than the correlation coefficients between ΔCT~L-S~ and ΔHS. Second, ΔCT~L-S~ measurements appear to be subject to a considerable measurement error. A wide range of ΔCT~L-S~ (−9.21--11.6) was noted even in patients with no HS during both the 1st and 2nd biopsy. Interobserver agreement with regard to the measurement of ΔCT~L-S~ was poorer than that associated with the measurement of CT~L-S~. Given these findings, we considered that a small change in ΔCT~L-S~ during a longitudinal follow-up assessment should not be considered meaningful. Therefore, we used the interobserver repeatability coefficient (i.e., ± 8.9) as the threshold for a meaningful change in CT~L-S~ beyond measurement error. In our study, the ΔCT~L-S~ beyond this threshold could detect a ≥5% or ≥10% change in HS, with a high specificity but a low to moderate sensitivity. Our findings, taken together, suggest that CT is not a reliable method for the longitudinal follow-up assessment of HS, but the change in CT~L-S~ beyond the measurement error range strongly indicates the true change in HS. Considering its low accuracy, potential hazard of ionizing radiation, and cost, performing CT examination in clinical practice for longitudinal follow-up assessment of HS would not be justified. Clinical indices less costly than CT, such as BMI, AST-ALT ratio, and HSI may be used as cost-effective alternatives to CT, since these indices showed significant correlations with the change in HS in our study. For clinical or research conditions where precise determination of the change in HS is critical, non-invasive imaging examinations with well-established diagnostic performance, such as MR spectroscopy or MR imaging,^\[[@R6],[@R7]\]^ would be preferred.

The measurement error of a quantitative imaging index should be determined in a repeatability condition in which a test is repeated within a short time interval to avoid true biologic changes in tested subjects.^\[[@R22]\]^ However, due to the risk of ionizing radiation, repeatedly performing CT scans over a short period is not practical in a research setting. Therefore, we considered the estimation of interobserver repeatability coefficient to be a more practical method to address the measurement error range of ΔCT~L-S~ in our study.

In our study, 2 abdominal radiologists and 2 medical school students were involved in the image review. The ICCs for the interobserver agreement of ΔCT~L-S~ were slightly stronger between the 2 radiologists than between the 2 students, but the difference was not statistically significant. Furthermore, the correlation coefficients between ΔCT~L-S~ and ΔHS were similar among the 4 readers. This finding indicates that CT~L-S~ measurement does not require much experience and can be relatively easily performed by readers with limited experience. We believe that the results obtained from readers with varying experience in this study facilitate generalization of our findings.

Our study has some limitations. First, our study involved multiple CT scanners and various scanning parameters. Given a significant influence of CT type/manufacturer on the measured liver attenuation in a previous study,^\[[@R9]\]^ the measurement error range of ΔCT~L-S~ revealed in our study may have been overestimated compared with the range obtained under typical conditions of measurement repeatability assessment. Second, the sample size in our study is relatively small. However, subjecting people with no liver abnormality, other than HS, to liver biopsy and CT multiple times is not recommended in clinical practice and will not be ethical for research. Therefore, despite the small size of study population, we believe that our study provides useful and valuable information regarding the feasibility and limitations of CT for the follow-up assessment of HS. Third, liver biopsy which served as the reference standard for HS assessment in our study may be subject to some degree of sampling error. Finally, our study was a retrospective study and, thus, is subject to selection bias.

In conclusion, the change in CT~L-S~ roughly reflects the change in HS during longitudinal follow-up. A small change in CT~L-S~ should not be considered meaningful because it may occur even without an actual change in HS. A larger change in CT~L-S~ beyond the measurement error range (± 8.9) strongly indicates the true change in HS.
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